Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00126243
Status:
TERMINATED
Last Update Posted:
2005-08-17
First Post:
2005-08-02
Brief Title:
Efficacy of Rituximab and Cyclophosphamide Doxorubicin Vincristine Prednisone CHOP in Patients With HIV Associated Non-Hodgkins Lymphoma
Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Organization:
French National Agency for Research on AIDS and Viral Hepatitis
Study Overview
Official Title:
Multicenter Open Label Phase II Trial to Evaluate the Efficacy and Safety of Treatment With Rituximab CHOP Regimen in Patients With HIV Related Non-Hodgkins Lymphomas ANRS 085 Rituximab
Status:
TERMINATED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Most treatment procedures in AIDS-related lymphomas disclose a relatively poor outcome for patients with low response rates high number of relapses and AIDS events The addition of rituximab to the standard regimen - CHOP could improve the outcome of these patients The aim of the trial is to evaluate the safety and efficacy of rituximab when added to the CHOP regimen in patients with newly diagnosed AIDS-related non-Hodgkin lymphoma
Detailed Description:
HIV infection is associated with a high incidence of AIDS-related lymphomas ARL Since the use of highly active antiretroviral therapy HAART the incidence of AIDS-defining illnesses has decreased leading to a significant improvement in survival of HIV-infected patients The incidence of ARL has decreased in a lower degree and lymphoma remains the major cause of death of HIV patients Most treatment procedures disclose a relatively poor outcome of patients with low response rates high number of relapses and AIDS events Since the majority of HIV-associated NHL are CD20-positive the addition of rituximab to the standard regimen - CHOP could improve the outcome of these patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None